Remarkably, we also found elevated levels of SREBP2 in the surviving cells, or cancer stem cells, compared to cells before cytotoxicity or in bulk cells, and observed greater nuclear translocation of SREBP2 in the surviving cells, cancer stem cells compared to cells before cytotoxicity or CD133− cells (Fig. 2C,D). This evidence concerns the gene SREBF2 and cancer.